These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15948036)

  • 1. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses.
    Coates MS; Fletcher DF; Chan HK; Raper JA
    Pharm Res; 2005 Jun; 22(6):923-32. PubMed ID: 15948036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size.
    Coates MS; Chan HK; Fletcher DF; Raper JA
    J Pharm Sci; 2006 Jun; 95(6):1382-92. PubMed ID: 16625656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses.
    Coates MS; Chan HK; Fletcher DF; Raper JA
    Pharm Res; 2005 Sep; 22(9):1445-53. PubMed ID: 16132356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length.
    Coates MS; Fletcher DF; Chan HK; Raper JA
    J Pharm Sci; 2004 Nov; 93(11):2863-76. PubMed ID: 15389665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler.
    Coates MS; Chan HK; Fletcher DF; Chiou H
    Pharm Res; 2007 Aug; 24(8):1450-6. PubMed ID: 17404813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols.
    Chew NY; Chan HK
    Pharm Res; 1999 Jul; 16(7):1098-103. PubMed ID: 10450937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of solid corrugated particles to enhance powder aerosol performance.
    Chew NY; Chan HK
    Pharm Res; 2001 Nov; 18(11):1570-7. PubMed ID: 11758765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.
    Parumasivam T; Leung SS; Tang P; Mauro C; Britton W; Chan HK
    AAPS J; 2017 Jan; 19(1):191-202. PubMed ID: 27679516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Different Effects of Inhaler Design on the Aerosol Performance of Drug-Only and Carrier-Based DPI Formulations. Part 1: Grid Structure.
    Leung CMS; Tong Z; Zhou QT; Chan JGY; Tang P; Sun S; Yang R; Chan HK
    AAPS J; 2016 Sep; 18(5):1159-1167. PubMed ID: 27161214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).
    Zhou QT; Tong Z; Tang P; Citterio M; Yang R; Chan HK
    AAPS J; 2013 Apr; 15(2):511-22. PubMed ID: 23371759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carrier particle emission and dispersion in transient CFD-DEM simulations of a capsule-based DPI.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2022 Jan; 168():106073. PubMed ID: 34774996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the motion of hard-shell capsules in dry powder inhalers.
    Benque B; Khinast JG
    Int J Pharm; 2019 Aug; 567():118481. PubMed ID: 31260784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer(®).
    Jiang L; Tang Y; Zhang H; Lu X; Chen X; Zhu J
    J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):265-79. PubMed ID: 22280548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2021 Jan; 156():105574. PubMed ID: 32980431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders.
    Chew NY; Bagster DF; Chan HK
    Int J Pharm; 2000 Sep; 206(1-2):75-83. PubMed ID: 11058812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
    Chew NY; Chan HK
    J Aerosol Med; 2001; 14(4):495-501. PubMed ID: 11791690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the mouthpiece and chamber of Turbuhaler® on the aerosolization of API-only powder formulations.
    Zhu Q; Gou D; Chan HK; Kourmatzis A; Yang R
    Int J Pharm; 2023 Apr; 637():122871. PubMed ID: 36948474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.